Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: The largest multicenter retrospective analysis of survival and prognostic factors

To compare the efficacy of sorafenib and sunitinib with regard to overall survival (OS) and progression free survival (PFS) in Chinese patients with metastatic renal cell carcinoma (mRCC). Sorafenib and sunitinib are both effective in treating mRCC. However, sorafenib might be more effective in elderly patients (≥65 years) and in patients with an ECOG status of 0, classified under MSKCC moderate risk.